Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry
- PMID: 28166611
- DOI: 10.1111/resp.12989
Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry
Abstract
Background and objective: Studies analysing the effect of worsening pulmonary physiological impairment in idiopathic pulmonary fibrosis (IPF) with respect to quality of life have been limited to single centres or highly selected trial populations. The aim of this study was to determine the principal determinants of baseline and longitudinal health-related quality of life (HRQoL) in a large unselected IPF population.
Methods: We used the Australian IPF Registry to examine the relationship between HRQoL, measured using the St George Respiratory Questionnaire (SGRQ), and demographic features, physiological features, co-morbidities and symptoms. Linear regression analysis was performed to identify predictors of baseline HRQoL, linear mixed model analysis to determine the effect of time and forced vital capacity (FVC) on SGRQ and Cox proportional hazards regression to examine the relationship between HRQoL and all-cause mortality.
Results: Baseline data from 516 patients were available (347 males; mean (SD) age: 71.3 ± 8.6 years). Univariate analysis showed significant associations between HRQoL and demographic, clinical and physiological features. However, multivariate analysis demonstrated independent associations only between SGRQ and dyspnoea (University of California San Diego Shortness of Breathlessness Questionnaire (UCSD-SOBQ); R2 = 0.71, P < 0.0001), cough severity (visual analogue scale; R2 = 0.06, P < 0.0001) and depression (Hospital Anxiety and Depression Scale; R2 = 0.04, P < 0.0001). Linear mixed-effects modelling of combined baseline and longitudinal data confirmed these associations, as well as for FVC% predicted (P = 0.005). Multivariate Cox proportionate-proportional hazards regression analysis demonstrated no association between HRQoL and risk of mortality.
Conclusion: Cough, dyspnoea and depression are major symptomatic determinants of HRQoL in IPF. FVC decline is associated with worsening HRQoL.
Keywords: cough; dyspnoea; forced vital capacity; pulmonary fibrosis; quality of life.
© 2017 Asian Pacific Society of Respirology.
Comment in
-
Maintaining quality of life in IPF patients: What role should pulmonary rehabilitation play?Respirology. 2017 Jul;22(5):841-842. doi: 10.1111/resp.13088. Epub 2017 May 25. Respirology. 2017. PMID: 28544193 No abstract available.
Similar articles
-
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.Respir Res. 2017 Jul 14;18(1):139. doi: 10.1186/s12931-017-0621-y. Respir Res. 2017. PMID: 28709421 Free PMC article.
-
The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry.Respir Res. 2019 Mar 15;20(1):59. doi: 10.1186/s12931-019-1020-3. Respir Res. 2019. PMID: 30876420 Free PMC article.
-
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.Respir Res. 2020 Jan 30;21(1):36. doi: 10.1186/s12931-020-1298-1. Respir Res. 2020. PMID: 32000772 Free PMC article. Clinical Trial.
-
Etiology and treatment of cough in idiopathic pulmonary fibrosis.Respir Med. 2017 Feb;123:98-104. doi: 10.1016/j.rmed.2016.12.016. Epub 2016 Dec 24. Respir Med. 2017. PMID: 28137504 Review.
-
Chronic breathlessness in patients with idiopathic pulmonary fibrosis: a major challenge for caregivers.Expert Rev Respir Med. 2016 Dec;10(12):1295-1303. doi: 10.1080/17476348.2016.1251843. Epub 2016 Nov 2. Expert Rev Respir Med. 2016. PMID: 27766905 Review.
Cited by
-
Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.Respir Res. 2019 Oct 24;20(1):231. doi: 10.1186/s12931-019-1182-z. Respir Res. 2019. PMID: 31651324 Free PMC article. Clinical Trial.
-
Clinical and economic burden of acute exacerbations of idiopathic pulmonary fibrosis: a prospective observational study in Spain (OASIS study).BMC Pulm Med. 2024 Jul 31;24(1):370. doi: 10.1186/s12890-024-03186-4. BMC Pulm Med. 2024. PMID: 39080648 Free PMC article.
-
Physical activity in idiopathic pulmonary fibrosis: Longitudinal change and minimal clinically important difference.Chron Respir Dis. 2023 Jan-Dec;20:14799731231221818. doi: 10.1177/14799731231221818. Chron Respir Dis. 2023. PMID: 38108832 Free PMC article.
-
Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis.Eur Respir Rev. 2024 Oct 9;33(174):230265. doi: 10.1183/16000617.0265-2023. Print 2024 Oct. Eur Respir Rev. 2024. PMID: 39384304 Free PMC article.
-
The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument.Qual Life Res. 2023 Jun;32(6):1609-1619. doi: 10.1007/s11136-022-03331-8. Epub 2022 Dec 26. Qual Life Res. 2023. PMID: 36572788
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources